Treating cancer more selectively and more effectively – this could be achieved with an innovative technology developed by teams of researchers at the Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) and the Ludwig-Maximilians-Universität München (LMU). The process transforms proteins and antibodies into stable, highly functional drug transporters, with which tumor cells can be detected and killed.
Classic chemotherapy for the treatment of cancer is based on toxic substances that are particularly effective for rapidly dividing cells. However, since healthy tissue also depends on cell division, treatment with chemotherapeutic substances is often accompanied by severe side effects. A dose sufficient to completely remove the tumor, would in many cases be too toxic to administer to a diseased person. With more modern approaches, it is now possible to transport active agents (drugs) in the body selectively to the site of action, for example by linking a drug with an antibody that can differentiate cancer cells from healthy tissue through changes on the surface of the cell. Five such Antibody Drug Conjugates (ADCs) are already on the market.
However, these ADCs lose a large part of their “toxic cargo” en route to the cancer cell. The substances (drugs) are released into the bloodstream and dangerous side effects can occur. A stable link between drug and antibody would therefore be highly desirable. This is precisely what the researchers – a team led by Professor Christian Hackenberger from the FMP and Professor Heinrich Leonhardt from the LMU Biocenter – focused on. Their results have been published in the prestigious journal, Angewandte Chemie: In two consecutive articles, the development of methods and the application of these methods to selective drug transport are presented.
The new drug transporters enable lower doses and less severe side effects
“We have developed an innovative technology that makes it possible to link native proteins and antibodies to complex molecules, such as fluorescent dyes or drugs more easily and with better stability than ever before,” reports Marc-André Kasper, a researcher in Christian Hackenberger’s group. The researchers discovered the outstanding properties of unsaturated phosphorus (V) compounds and took advantage of those. These phosphonamidates connect a desired modification – for example, a cancer-fighting agent – exclusively to the amino acid cysteine, in a protein or antibody. Since cysteine is a very rare natural occurring amino acid, the number of modifications per protein can be controlled quite effectively, which is essential for the construction of drug conjugates. In addition, phosphonamidates can easily be incorporated into complex chemical compounds. “The greatest achievement of the new method, however, is that the resulting bond is also stable during blood circulation,” says Marc-André Kasper. The ADCs that are on the market cannot achieve this.
To test the applicability on targeted drug delivery, the researchers compared their technology directly with the FDA-approved ADC, Adcetris®. The medication was re-created as precisely as possible with the same antibody and active agent, the only difference was that the innovative phosphonamidate linkage was used. When applied to blood serum, the researchers observed that their modified ADC lost significantly less active ingredient over a period of days. They also used the new technology in experiments with mice to combat Hodgkin’s lymphoma. The preparation proved to be more effective than the conventional medication. “From our results, we conclude that phosphonamidate-linked drug transporters can be administered in lower doses, and that side effects can be further reduced. Thus the technology has great potential to replace current methods in order to develop more effective and safer ADCs in the future,” says FMP group leader Christian Hackenberger.
In the next step, the research groups will continue their efforts in the development of ADCs based on phosphonamidates. Preclinical studies, which are essential for the treatment of patients, are already underway. In this regard, the promising start-up company Tubulis, which was awarded the Leibniz Start-Up Prize last year, functions as a platform for the further development to market maturity.
The Latest on: Antibody Drug Conjugates
via Google News
The Latest on: Antibody Drug Conjugates
- FDA Grants Breakthrough Therapy Designation to IMGN632 in Relapsed/Refractory Blastic Plasmacytoid Dendritic Cell Neoplasmon October 5, 2020 at 1:06 pm
The FDA has granted a breakthrough therapy designation to IMGN632 for the treatment of patients with relapsed or refractory blastic plasmacytoid dendritic cell neoplasm.
- ImmunoGen Announces FDA Breakthrough Therapy Designation for IMGN632 in Relapsed or Refractory Blastic Plasmacytoid Dendritic Cell Neoplasmon October 5, 2020 at 4:30 am
ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, today announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy ...
- Goldman Sachs Has 5 Stocks to Buy Under $10 With 100% or More Upside Potentialon October 3, 2020 at 7:15 am
The towering $15 Goldman Sachs price target compares to the even higher $18.50 consensus target. Shares traded mostly below $7 last week. Hitting the Goldman Sachs target would be a massive 120% gain.
- Elucida Oncology Appoints Dr. Eliel Bayever as Chief Medical Officeron October 1, 2020 at 12:32 pm
Elucida Oncology, a biotechnology company pioneering the next frontier in targeted cancer therapy, announced today the appointment of Dr. Eliel Bayever as Chief Medical Officer effective immediately.
- Gynecologic Oncologists Continue to Pursue Novel Agents, Immunotherapy in Ovarian Canceron September 30, 2020 at 1:47 pm
Caroline Billingsley, MD, spoke to established and emerging treatment modalities in ovarian cancer and the successes and pitfalls of key clinical trials of antibody-drug conjugates and immunotherapy ...
- Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discusson September 25, 2020 at 9:20 am
In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of ...
- Roche antibody-drug conjugate OK'd in Canada for aggressive type of blood canceron September 24, 2020 at 9:15 am
Health Canada has approved Roche's (OTCQX:RHHBY) antibody-drug conjugate Polivy (polatuzumab vedotin), combined with chemo agent bendamustine and Rituxan (rituximab), for the treatment of adult ...
- ADC Therapeutics Announces Pricing of Public Offeringon September 23, 2020 at 7:21 pm
ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates ...
- Antibody Drug Conjugates Market 2020E Report Including Covid-19 Impact Analysis And Forecast Till 2026E: Facts & Factorson September 23, 2020 at 1:15 am
Facts and Factors market research publisher releases a new research report on “New Survey Update Available in Antibody Drug Conjugates Market size & Share 2020 Analysis and Industry Forecast ...
- Global Antibody Drug Conjugates (ADCs) Market 2020 by Key Players, Segmentation, Industry Growth, Opportunities and Forecast by 2025on September 21, 2020 at 4:24 pm
A new report by MarketandResearch.biz titled, Global Antibody Drug Conjugates (ADCs) Market 2020 by Company, Regions, Type and Application, Forecast to 2025 has been released with trustworthy ...
via Bing News